The Weekly Roundup

March 04, 2016 | Pamela Youngberg Dickson

Generic drug ETF is falling in the market despite the heavy focus on drug pricing in Congress and among the presidential candidates. Meanwhile, on the brand front, the FDA has been busy with a new single-pill Hepatitis C treatment. While the labeling has extensive coverage of drug-on-drug interactions, pharmacists should be aware that interactions may lead to increases or reductions in exposure to elbasvir and/or grazoprevir. Here are a few more pieces we found this week we think might interest you:

Continue reading →